Home     About SABCS     Press Releases     Media     Event Photos     Past Symposia     Satellite Symposia     Patient Advocates     FAQs     Contact Us



Registration           Hotel           Late Breaking Abstract Submission     Support & Exhibits     2014 Overview           Program           Travel & Transportation          

Quick Links
Career Development Forum Reg Form
SABCS 2013 Program Book pdf

Schedule at a Glance
 
Daily Schedule:
Tue. 12/9/2014
Wed. 12/10/2014
Thu. 12/11/2014
Fri. 12/12/2014
Sat. 12/13/2014
 
Poster Sessions:
Poster Session 1
Poster Session 2
Poster Session 3
Poster Session 4
Poster Session 5
Poster Session 6
 
Poster Session OT1
Poster Session OT2
Poster Session OT3
 
Poster Discussions:
Poster Discussion 1
Poster Discussion 2
Poster Discussion 3
Poster Discussion 4
Poster Discussion 5
Poster Discussion 6
 

Program Schedule   >  Poster Sessions - Poster Session 3

Poster Session 3 
   
  Tumor Cell and Molecular Biology: Metabolism and Breast Cancer
P3-01-01 Targeting glutamine metabolism in breast cancer for therapy
Korangath P, Sadik H, Mori N, Wildes F, Zhang Z, Bhujwalla Z, Sukumar S. Johns Hopkins University, Baltimore, MD.
P3-01-02 Oxalate microcalcifications induce breast cancer tumors
Gil GA, Castellaro AM, Pucci O, Tonda A, Cejas H, Caputto BL. Ciquibic-Conicet, Facultad de Ciencias Químicas, Universidad Nacional de Cordoba, Cordoba, Argentina; Hospital Nacional de Clinicas, 1ra Cátedra de Ginecologia, Universidad Nacional de Cordoba, Cordoba, Argentina; Instituto Privado de Patología y HNC Cátedra de Patología UN Cordoba, Cordoba, Argentina. German A. Gil is a recipient of an Avon-AACR International Scholar-In-Training Award
P3-01-03 Vitamin D levels at breast cancer diagnosis: Association with patient and tumor characteristics
Cate SP, Berger N, Boolbol SK, Klein P, Gillego A, Estabrook A, Malamud S, Chadha M, Lucido D, Shao T. Beth Israel, New York, NY; University of Connecticut, Farmington, CT; St. Luke's-Roosevelt Hospital, New York, NY.
P3-01-04 Obesity induces functional transcriptomic changes enhancing the cancer hallmarks of estrogen receptor-positive breast cancer
Fuentes-Mattei E, Phan L, Velazquez-Torres G, Zhang F, Chou P-C, Shin J-H, Choi H-H, Chen J-S, Chen J, Gully C, Carlock C, Zhao R, Qi Y, Zhang Y, Wu Y, Esteva FJ, Lou Y, McKeehan WL, Ensor JE, Hortobagyi GN, Pusztai L, Symmans WF, Lee M-H, Yeung S-CJ. The University of Texas M.D. Anderson Cancer Center, Houston, TX; Texas A&M Health Science Center, Center for Cancer & Stem Cell Biology, Institute of Biosciences and Technology (IBT), Houston, TX.
P3-01-05 Metabolomic analysis of breast cancer cell lines: Clues to the metabolic fingerprint of inflammatory breast cancer
Mu Z, Brown MV, Fernandez S, Robertson FM, Cristofanilli M. Thomas Jefferson University and Kimmel Cancer Center, Philadelphia, PA; Metabolon, Inc, Durham, NC; The University of Texas, MD Anderson Cancer Center, Houston, TX.
P3-01-06 TIGAR induces two compartment metabolic coupling and tamoxifen resistance
Ko Y-H, Bombonati A, Martinez-Outschoorn UE. Thomas Jefferson University, Philadelphia, PA; Albert Einstein Medical Center, Philadelphia, PA.
P3-01-07 Metformin has an additive effect to cisplatin in triple negative breast cancer cells with high lactate dehydrogenase B (LDHB) expression
Harada N, Varghese V, Tharayil IA, Kenny L. Imperial College London, London, United Kingdom.
   
  Tumor Cell and Molecular Biology: Cell Cycle Regulation
P3-02-01 Pregnancy-associated plasma protein A regulates mitosis and is epigenetically silenced in breast cancer
Sainsbury R, Loddo M, Andryszkiewicz J, Widschwendter M, Stoeber K, Williams G. UCL Cancer Institute, Paul O'Gorman Building, University College London, London, United Kingdom; UCL Elizabeth Garrett Anderson Institute for Women's Health, University College London, London, United Kingdom.
P3-02-02 Cyclin D1 overexpression increases the risk for breast cancer death 4-fold in hormone receptor positive and node negative breast cancer
Ahlin C, Grönberg M, Valachis A, Zhou W, Amini R-M, Blomqvist C, Fjällskog M-L. Department of General Oncology, Örebro, Sweden; Section of Endocrine Oncology, Department of Medical Sciences, Uppsala, Sweden; Department of General Oncology, Eskilstuna, Sweden; Department of Surgical Science, Uppsala, Sweden; Department of Genetics and Pathology, Uppsala, Sweden; Department of Oncology, Helsinki, Finland; Department of Oncology, Uppsala, Sweden.
P3-02-03 The phosphatase function of the eyes absent (EYA) homolog is required for the induction of breast cancer cellular proliferation via cyclin D1
Pestell RG, Wu K, Li Z, Tian L, Chen K, Wang J, Hu J, Sun Y, Li X, Ertel A. Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei, China; Boston Children's Hospital, Boston, MA.
P3-02-04 QM-FISH analysis of the genes involved in the G1/S checkpoint signaling pathway in triple-negative breast cancer
Zhang J, Zhang S, Hou G, Shao Y, Zhang X. China Tianjin Breast Cancer Prevention, Treatment and Research Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; Key Laboratory of Breast Cancer Prevention and Therapy of Ministry of Education; Key Laboratory of Cancer Prevention and Therapy.
   
  Tumor Cell and Molecular Biology: Cellular Mechanisms
P3-03-01 The role of a newly discovered N-terminal methyltransferase in breast cancer
Bonsignore LA, Schaner Tooley CE. University of Louisville, Louisville, KY.
P3-03-02 Na+,HCO3−-cotransport is the major mechanism of cellular acid extrusion in human and murine breast cancer
Mele M, Lee S, Moreira J, Vahl P, Wielenga V, Jensen V, Pedersen S, Christiansen P, Aalkjær C, Boedtkjer E. Aarhus University Hospital, Aarhus C, Jutland, Denmark; Copenhagen University Hospital, Copenhagen, Zeeland, Denmark; Danish Cancer Society Research Center, Frederiksberg C, Zeeland, Denmark; Aarhus University, Aarhus C, Jutland, Denmark.
P3-03-03 Phenolic compounds from pimenta dioica berries (allspice) inhibit breast cancer cell proliferation by autophagy induction
Zhang L, Nagarajarao S, Lokeshwar B. University of Miami, Miami, FL.
P3-03-04 RNA sequencing reveals activation of NRF2 and ATF2/ATF3 transcriptional programs in response to DNA damage in breast cancer cells
Bernard XG, Zanotto-Filho A, Masamsetti P, Gorthi A, Loranc E, Bshop AJ. UTHSCSA, San Antonio, TX.
P3-03-05 Modulation of the metastatic propensity of triple-negative breast cancer cells harboring p53 mutations
Morrison BL, Tai JW, Bernal F. Center for Cancer Research - National Cancer Institute, Bethesda, MD.
P3-03-06 Targretin and 9-cis-UAB30 decrease invasion and migration in human breast cancer cells
Bode AM, Kim M-S, Grubbs CJ, Muccio DD, Lubet RA. University of Minnesota-The Hormel Institute, Austin, MN; University of Alabama at Birmingham, Birmingham, AL; National Cancer Institute, Bethesda, MD.
P3-03-07 Combination of eribulin and PI3K inhibitors in triple negative and HER2 expressing breast cancer cell lines results in synergistic growth inhibition and enhanced inhibition of the PI3K pathway
Luyimbazi D, Luu T, Xing Q, Yan J, Tully D, Han E, Yip RML, Yim JH. City of Hope National Medical Center, Duarte, CA.
P3-03-08 A comparison of PI3K inhibition by eribulin, other microtubule targeting agents and a DNA-damaging chemotherapeutic in triple negative and HER2 expressing breast cancer cell lines
Luyimbazi D, Luu T, Xing Q, Yan J, Tully D, Han E, Yip RML, Yim JH. City of Hope National Medical Center, Duarte, CA.
P3-03-09 Anti-proliferative dose of γ-tocotrienol decreases c-Myc stability in breast cancer cells
Parajuli P, Tiwari RV, Sylvester PW. University of Louisiana at Monroe, Monroe, LA.
P3-03-10 The multikinase inhibitor sorafenib enhances the cytotoxic effect of alkylation damage by inhibiting DNA-damage induced survival and inflammatory mediators in breast cancer cells
Zanotto-Filho A, Bernard X, Masamsetti P, Gorthi A, Loranc E, Bishop AJR. University of Texas Health Science Center at San Antonio - UTHSCSA, San Antonio, TX; Greehey Children's Cancer Research Institute, San Antonio, TX; Department of Cellular and Structural Biology, San Antonio, TX.
P3-03-11 Oxazine derivatives of γ- and δ- tocotrienols display potent anticancer effects in vivo
Ananthula S, Parajuli P, Behery FA, Ayoubi AAl, El Sayed KA, Nazzal SM, Sylvester PW. University of Louisiana at Monroe, Monroe, LA.
P3-03-12 Gamma-tocotrienol induces autophagy in malignant mammary tumor cells
Tiwari RV, Parajuli P, Sylvester PW. University of Louisiana at Monroe, Monroe, LA.
   
  Tumor Cell and Molecular Biology: DNA Damage and Repair
P3-04-01 Discovery of distinct sub-groups of ER positive breast cancers by DNA repair expression profiling: Implications for patient stratification and personalization of therapy
Madhusudan S, Abdel-Fatah TMA, Russell R, Moseley P, Agarwal D, Mukherjee A, Ball G, Abbotts R, Perry C, Caldas C, Rakha EA, Chan S, Ellis IO. University of Nottingham, Nottingham University Hospitals, Academic Unit of Oncology, School of Medicine, Nottingham, United Kingdom; Nottingham University Hospitals, Nottingham, United Kingdom; Cancer Research UK, Cambridge Research Institute, Cambridge, United Kingdom; Nottingham Trent University, School of Science and Technology, Nottingham, United Kingdom; University of Nottingham, Nottingham University Hospitals, Division of Pathology, School of Medcine, Nottingham, United Kingdom.
P3-04-02 Absence of PTEN facilitates the anti-tumor efficacy of GDC-0980 in combination with ABT888 plus carboplatin in BRCA1-competent triple negative breast cancer
Dey N, Sun Y, Carlson J, Friedman L, De P, Leyland-Jones B. Edith Sanford Breast Cancer Research/Sanford Research/USD, Sioux Falls, SD; Genentech Inc, San Fransisco, CA.
P3-04-03 Withdrawn
P3-04-04 Amplification and overexpression of TLK2 promote genomic instability in invasive breast cancer
Kim J-A, CAO X, Tan Y, Wang X, Schiff R, Wang X. Baylor College of Medicine, Houston, TX.
P3-04-05 Amplification driven expression of KIAA0020, a PARP1 interacting gene, facilitates repair of replication associated DNA damage in triple-negative breast cancers
Grigoriadis A, Noel E, Weekes D, Shah V, Sidhu B, Gazinska P, Watkins J, Marra P, Tutt A. Breakthrough Breast Cancer Unit; Research Oncology, Integrated Cancer Centre, Guy's Hospital, King's College London, School of Medicine, London, United Kingdom.
P3-04-06 Damage-induced BRCA1 phosphorylation contributes to the timing of end resection
Parameswaran B, Chiang H-C, Lu Y, Hu Y. University of Texas Health Science Center at San Antonio, San Antonio, TX.
P3-04-07 Functional BRCA-pathway defects in sporadic breast cancers rarely show a significant reduction in BRCA-pathway proteins
Powell SN, Mutter RW, Delsite R, Reis-Filho JS. Memorial Sloan-Kettering Cancer Center, New York, NY.
P3-04-08 A proteo-probe for nucleotide excision repair in breast cancers
Dreze M, Calkins AS, Echelman DJ, Schnorenberg MR, Fell GL, Fisher DE, Iglehart JD, Lazaro J-B. Dana-Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA; Massachusetts General Hospital, Charlestown, MA.
   
  Prognosis and Response Prediction: Biomarkers - Methods
P3-05-01 Accurate assessment of HER2 status in "triple-negative" breast cancer requires both IHC and FISH testing
Ren Q, Alexander M, Samdani R, Singh B. New York University School of Medicine, New York, NY.
P3-05-02 HER2 copy number on FISH as a predictor of disease severity in HER2- breast cancer
Abedin S, Kruse M, Brufsky A, Bhargava R. University of Michigan Health System, Ann Arbor, MI; University of Pittsburgh Medical Center, Pittsburgh, PA.
P3-05-03 HER2-CONNECT® pathologist-assisted image analysis algorithm for HER2 IHC interpretation improves correlation with HER2 FISH results
Miller DV, Stender H, Kristensen T, Min RK, Isaac J, Hansen J, Seaman J, Grunkin M, Vyberg M. Intermountain Healthcare, Salt Lake City, UT; Visiopharm, Hoersholm, Denmark; Aalborg University Hospital, Aalborg, Denmark.
P3-05-04 Withdrawn
P3-05-05 Classification using dynamic re-discovery of the strongest prognostic features in each analysis outperforms static gene expression signatures for prognostic prediction in breast cancer
Györffy B, Karn T, Sztupinszki Z, Weltz B, Müller V, Pusztai L. Hungarian Academy of Sciences; J. W. Goethe-University; University of Hamburg; Yale Cancer Center.
P3-05-06 A better clinical cutpoint for progesterone receptor expression in tamoxifen treated breast cancer
Kornaga EN, Paterson AHG, Morris DG, Magliocco AM, Klimowicz AC. Translational Research Laboratories, Alberta Health Services, Calgary, AB, Canada; University of Calgary, Calgary, AB, Canada; Anatomic Pathology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT.
P3-05-07 Improved risk stratification for breast cancer samples based on the expression ratio of the estrogen and progesterone receptor: A case control study
Niendorf A, Treszl A, Friedrichs K, Lindner C, Bendrat K. Pathologie Hamburg-West, Hamburg, Germany; Institut für Medizinische Biometrie und Epidemiologie, UK Eppendorf, Hamburg, Germany; Mammazentrum Hamburg, KH Jerusalem, Hamburg, Germany; Diakonie-Klinikum Hamburg, Hamburg, Germany.
P3-05-08 Discordance in hormone receptor (HR) assessment by IHC and RT-PCR in an estrogen receptor (ER) low-positive group (1-10% positive cells): Does accurate assessment of HR status require dual testing?
Singh B, Ziguridis N, Axelrod D, Butler SM, Jamshidian F, Charbavaz DB, Sing AP, Baehner FL. New York University School of Medicine, New York, NY; Genomic Health, Inc., Redwood City, CA.
P3-05-09 Interlaboratory variability of Ki67 labeling index in breast cancer tissue microarrays
Focke CM, Gläser D, Finsterbusch K, Bürger H, Korsching E, Berghäuser K-H, Hinrichs B, Krause U, Lorenzen J, Packeisen J, van Diest PJ, Decker T. Dietrich Bonhoeffer Medical Center, Neubrandenburg, Neubrandenburg, Germany; Institute of Pathology, Paderborn, Paderborn, Germany; Institute of Bioinformatics, University of Münster, Münster, Germany; Institute of Pathology, Thüringen-Hospital Georgius Agricola, Saalfeld, Saalfeld, Germany; Medical Care Center for Pathology and Cytology, Köln, Köln, Germany; Städtisches Klinikum Dessau, Dessau, Germany; Institute of Pathology, Klinikzentrum Mitte, Dortmund, Germany; Joint Practice for Pathology, Osnabrück, Osnabrück, Germany; University Medical Center Utrecht, Utrecht, Netherlands.
P3-05-10 The development of a standardized Ki-67 assay for the ALTERNATE trial: An experience in academic investigational device development
Goncalves R, Ma CX, Tao Y, Suman VJ, Barnes M, Sanati S, Allred DC, Crouch E, DeSchryver K, Ellis MJ. Washington University School of Medicine, St Louis, MO; Mayo Clinic, Rochester, MN; Ventana Medical Systems, Tucson, AZ.
P3-05-11 Comparison of Ki67 counted by digital pathology image analysis software application and scores determined by pathologists
Niikura N, Kumaki N, Masuda S, Xiaoyan T, Miyazawa M, Iwamoto T, Okamura T, Saito Y, Tokuda Y. Tokai University School of Medicine, Isehara, Kanagawa, Japan; Nihon University School of Medicine, Tokyo, Japan; Okayama University Hospital, Okayama, Japan.
P3-05-12 Withdrawn
P3-05-13 Withdrawn
P3-05-14 Recognition of glycan-epitopes by the macrophage glycoreceptor CLEC10A is associated with improved outcome in primary breast cancer
Nollau P, Bendrat K, Klampe B, Friedrichs K, Lindner C, Wagener C, Niendorf A. University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Pathologie Hamburg-West, Hamburg, Germany; Mammazentrum Hamburg am Jerusalem Krankenhaus, Hamburg, Germany; Agaplesion Diakonieklinikum Hamburg, Hamburg, Germany.
P3-05-15 TP53 mutation and nestin protein expression patterns affect the outcome of patients with triple negative breast cancer (TNBC)
Koletsa T, Razis E, Lakis S, Kostopoulos I, Bobos M, Chrisafi S, Christodoulou C, Kotoula V, Fountzilas G, Pectasides D. Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece.
P3-05-16 Quantitative diagnostic technology for HER2 positive breast cancer by molecular imaging: The potential predictive factor of anti-HER2 therapy
Miyashita M, Gonda K, Tada H, Watanabe M, Ishida T, Sasano H, Ohuchi N. Tohoku University.
   
  Epidemiology, Risk, and Prevention: Epidemiology - Population
P3-06-01 Association between metformin use and improved survival in breast cancer patients: A population-based study
Li YR, Tchou J. Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
P3-06-02 The use of imaging and tumor markers in the staging of patients age <65 years with early-stage breast cancer
Barcenas CH, Niu J, Valero V, Smith B, Giordano SH. University of Texas MD Anderson Cancer Center, Houston, TX.
P3-06-03 Oral bisphosphonates and survival of breast and colon malignancies
Rennert G, Rennert HS, Pinchev M, Flugelman A, Kershenbaum A, Landsman K, Hadad R, Shulman K, Gruber SB. Carmel Medical Center and Bruce Rappaport Faculty of Medicine, Technion–Israel Institute of Technology and Clalit National Cancer Control Center, Haifa, Israel; Carmel Medical Center, Haifa, Israel; Hilel Yaffe Medical Center, Hadera, Israel; USC Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA.
P3-06-04 Differences in survival among women with primary and secondary metastatic breast cancer
Barinoff J, Schmidt M, Schneeweiss A, Hinke A, Schoenegg W, Henken S, Kutscheidt A, Pintoffl J, Jackisch C. Kliniken Essen Mitte, Essen, Germany; University Medical Center of the Johannes Gutenberg University, Mainz, Germany; Heidelberg University Faculty od Medicine, Heidelberg, Germany; WiSP Wissenschaftlicher Service Pharma GmbH, Langenfeld, Germany; Gynecological Practice, Berlin, Germany; Roche Pharma AG, Grenzach Wyhlen, Germany; Clinic for Gynecology & Obstetric, Offenbach, Germany.
P3-06-05 HER2/HR positive early breast cancer patients have nowadays the highest disease-free survival: Results from the south-east of the Netherlands
Tjan-Heijnen VCG, Lobbezoo DJA, Dercksen M, Voogd AC, van den Berkmortel F, van de Wouw AJ, van Kampen RJW, Peer PGM. Maastricht University Medical Center, Maastricht, Netherlands; Máxima Medical Center, Eindhoven, Netherlands; Atrium Medical Center Parkstad, Heerlen, Netherlands; VieCuri Medical Center, Venlo, Netherlands; Orbis Medical Center, Sittard, Netherlands; Radboud University Nijmegen Medical Center, Nijmegen, Netherlands.
P3-06-06 Withdrawn
P3-06-07 All-cause costs among elderly breast cancer patients by receipt of human epidermal growth factor receptor 2-targeted therapy: An analysis of US national data 2006-2009
Lang K, Hao Y, Huang H, Federico V, Menzin J. Boston Health Economics, Inc., Waltham, MA; Novartis Pharmaceuticals Corporation, East Hanover, NJ.
P3-06-08 Patterns of health care utilization and costs by chemotherapy and endocrine therapy sequencing among patients with hormone receptor positive (HR+)/HER2- negative advanced breast cancer
Engel-Nitz NM, Hao Y, Gomez Rey G, Sullivan J, Willemann Rogerio J. OptumInsight, Eden Prairie, MN; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Allina Health, Formerly Employee of OptumInsight, Minneapolis, MN.
P3-06-09 Survival among patients with hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer: A real-world observational study
Engel-Nitz NM, Hao Y, Gomez Rey G, Sullivan J, Willemann Rogerio J. OptumInsight, Eden Prairie, MN; Novartis Pharmaceutical Services, East Hanover, NJ; Allina Health, Formerly Employed by OptumInsight, Minneapolis, MN.
P3-06-10 All-cause resource use among elderly breast cancer patients by receipt of human epidermal growth factor receptor 2-targeted therapy: An analysis of US national data 2006-2009
Hao Y, Lang K, Huang H, Federico V, Menzin J. Novartis Pharmaceuticals Corporation, East Hanover, NJ; Boston Health Economics, Inc., Waltham, MA.
P3-06-11 Disease and treatment characteristics of a large insured female population with advanced or metastatic breast cancer by receipt of HER2-targeted agents
Hao Y, Landsman-Blumberg P, Meyer N, Johnson W, Willemann Rogerio J. Novartis Pharmaceuticals, East Hanover, NJ; Truven Health Analytics, Cambridge, MA; Truven Health Analytics, Washington, DC.
P3-06-12 Estimating prevalence of stage II-III breast cancer in the United States by treatment and biologic subtypes using oncology clinic data
Quigley J, Hernandez RK, Pirolli M, Quach D, Liede A. IMS Health, Plymouth Meeting, PA; Center for Observational Research, Amgen, Inc., Thousand Oaks, CA; Center for Observational Research, Amgen, Inc., South San Francisco, CA.
P3-06-13 Transient increase in breast cancer risk after a full term pregnancy among African women
Sighoko D, Hou N, Ogundiran T, Adebamowo C, Ademola A, Ojengbede O, Anetor I, Akinleye S, Ndom P, Gakwaya A, Huo D, Olopade OI. The University of Chicago, Chicago, IL; University of Chicago, Yaounde, Center, Cameroon; Mulago Hospital, Kampala, Uganda; The University of Ibadan, Ibadan, Nigeria; University of Maryland, Baltimore, MD.
P3-06-14 Increase in the proportion of stage IV breast cancer amongst young women with newly diagnosed breast cancer, report from the National cancer data base, 1998-2009
Yao K, Tomasz C, Pesce C, Huo D, David WJ, David WP, Edward W. NorthShore University HealthSystem, Evanston, IL; University of Chicago, Chicago, IL.
P3-06-15 Breast cancer molecular profile according to BMI and menopausal status
Arpino G, Crispo A, De Angelis C, Thomas R, De Laurentiis M, Forestieri V, Colao A, De Placido S. University of Naples "Federico II", Naples, Italy; National Cancer Institute "Fondazione Pascale", Naples, Italy; "Clinica Mediterranea" Hospital, Naples, Italy.
P3-06-16 The difference of molecular subtypes and prognosis after surgery for breast cancer patients with each blood types
Kondo N, Fujita T, Sawaki M, Hattori M, Horio A, Gondo N, Idota A, Ichikawa M, Iwata H. AIichi Cancer Center Hospital, Nagoya, Aichi, Japan.
P3-06-17 Pattern of distant metastases, including brain, in a population-based cohort of breast cancer patients, by initial stage at diagnosis
Landis SH, Casso D, Nelson JJ, Wells KE, Oliveria SA, Yood MU. GlaxoSmithKline, Uxbridge, United Kingdom; Episource, Newton, MA; GlaxoSmithKline, Research Triangle Park, NC; Henry Ford Health System, Detriot, MI.
P3-06-18 The health of women study: A novel approach to the cohort study
Love SM, Sykes N, Fischetti CA, Sullivan-Halley J, Clague J, Bernstein L. Dr. Susan Love Research Foundation, Santa Monica, CA; City of Hope Comprehensive Cancer Center, Duarte, CA.
P3-06-19 Large-scale retrospective analysis between 1980-2008 in 20 838 women with breast cancer – Results in young women (< 40 years old)
Lerebours F, Stevens D, Jouanneau L, Guerard A, De La Lande B, Cherel P, Lasry S, Guinebretière J-M, Noguès C, Mouret-Fourme E. Institut Curie, Hôpital René Huguenin, Saint-Cloud, France.
P3-06-20 The correlation between body mass index (BMI) and breast cancer in both premenopausal and menopausal women in Okinawa
Tamaki K, Tamaki N, Kamada Y, Uehara K, Sasano H, Ishida T, Miyashita M, Ohuchi N. Nahanishi Clinic Okinawa, Naha, Okinawa, Japan; Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
P3-06-21 The use of geographic information system in comprehension of spatial dependence in the mortality rate caused by breast cancer for female population in Rio de Janeiro - Brazil
Bello MA, Andrade CLT. Brazilian National Cancer Institute, Rio de Janeiro, Brazil; National School of Public Health Sergio Arouca (ENSP) - Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
P3-06-22 The time interval between age at first birth and age at diagnosis was associated with a decrease in breast cancer survival for all breast cancer subtypes: A register based study from Korea
Lee J, Oh M, Kim S, Kim W, Lee J, Kim W. Haeundae Paik Hospital, College of Medicine, University of Inje, Busan, Republic of Korea; College of Medicine, University of Inje, Clinical Trial Center, Busan, Republic of Korea.
P3-06-23 Primary breast sarcoma: Clinicopathological outcomes from the Philippine General Hospital and review of literature
Manalo MOU, Agana MAE, Fernando GY. UP-Philippine General Hospital, Manila, Philippines.
P3-06-24 Decrease of mortality from breast cancer in Brazil: Data from a population-based cancer registry
Ismael GV, Coradazzi AL, Mattos ÉR, Cantarelli A, Beato CM, Ikoma MV, Veneziano DB, Caldeira JRF, Segalla JGM. Fundação Dr Amaral Carvalho, Jaú, Sao Paulo, Brazil.
   
  Epidemiology, Risk, and Prevention: Epidemiology - Genetic and Molecular
P3-07-01 Family history of breast cancer in a population-based breast cancer cohort: No association with PAM50 intrinsic subtype or prognosis
Sweeney C, Bernard PS, Kwan ML, Factor RE, Quesenberry CP, Habel LA, Kroenke CH, Weltzien EK, Castillo A, Kushi LH, Caan BJ. University of Utah, Salt Lake City, UT; Kaiser Permanente Northern California, Oakland, CA.
P3-07-02 Increased risk of secondary cancers in patients with breast cancer under age 50 and the identification of non-BRCA inherited cancer syndromes using multi-gene hereditary cancer panels
Diab S, Stuenke A, Kagey J, Hamlington B, Keiles S, Freivogel M, Asmar L, Langer L. Rocky Mountain Cancer Centers, Aurora and Denver, CO; US Oncology Research and Genetic Risk Evaluation and Testing Program (GREAT), The Woodlands, TX; Ambry Genetics, Aliso Viejo, CA; Compass Oncology, Portland, OR; Invision Sally Jobe, Englewood, CO.
P3-07-03 Insulin-like growth factor-1 receptor variant associated with decreased breast cancer risk in women with pregnancy-induced hypertension
Powell M, Benz C, Ereman R, Prebil LA, Jamshidian F, Rose S. Marin County Health & Human Services, San Rafael, CA; Buck Institute for Research on Aging, Novato, CA.
P3-07-04 Impact of estrogen receptor (ER) and HER2 co-expression on breast cancer characteristics and disease presentation
Al-Qaisi A, Chen L, Romond E, Stevens M, Pasley G, Massarweh S. University of Kentucky and Markey Cancer Center, Lexington, KY.
P3-07-05 Frequent BRCA1 and BRCA2 mutations are found in Mexican and Mexican-American women with breast cancer
Chaudhury A, Laukaitis C, Mauss C, Walsh T, Casadei S, Thompson P, Lopez AM, Navarro AD, King M-C. University of Arizona, Tucson, AZ; University of Arizona Cancer Center, Tucson, AZ; University of Washington, Seattle, WA; Centro Universitario De Ciencias De La Salud Universidad De Guadalajara Sierra Mojada No 950, Edificio P Primer Niviel, Colonia Independencia, Guadalajara, Jalisco, Mexico.
P3-07-06 BRCA mutations among Hispanic breast cancer patients of Mexican origin in El Paso, TX
Nahleh ZA, Heydarian R, Saldivar JS, Castaneda K, Sanchez L. Texas Tech University Health Sciences Center/Paul L. Foster School of Medicine, El Paso, TX.
P3-07-07 Single nucleotide polymorphisms of BRCA1-interacting genes are associated with triple-negative breast cancer in Chinese Han woman
Ling H, Hu X, Shao Z-M. Fudan University Shanghai Cancer Center, Shanghai, China.
P3-07-08 Breast cancer in China reveals transcriptomic likeness to Caucasian breast cancer
Huang X, Dugo M, Callari M, Sandri M, DeCecco L, Carcangiu ML, Iorio M, Xue J, Daidone MG, Ménard S, Tagliabue E, Wu J, Orlandi R. Fudan University/Shanghai Cancer Center, and Shanghai Medical College, Fudan University, Shanghai, China; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
P3-07-09 Breast cancer susceptibility associated single nucleotide polymorphisms (SNPs) and prognosis: GG genotype of a SNP rs3803662 (TOX3/TNRC9) associated with better survival
Lee JW, Moon H-G, Han W, Noh D-Y. Seoul National University Hospital, Seoul, Republic of Korea.
P3-07-10 Breast cancer risk-related gene polymorphisms, ESR1/6q25.1-rs2046210 and rs3757318, and clinical characteristics of breast cancer patients
Taira N, Mizoo T, Nishiyama K, Nogami T, Iwamoto T, Motoki T, Shien T, Matsuoka J, Doihara H, Ishihara S, Kawai H, Kawasaki K, Ogasawara Y, Ishibe Y. Okayama University Hospital, Okayama, Japan; Okayama Saiseikai General Hospital, Okayama, Japan; Okayama Rosai Hospital, Okayama, Japan; Kagawa Prefectural Central Hospital, Takamatsu, Kagawa, Japan; Mizushima Kyodo Hospital, Kurashiki, Okayama, Japan.
P3-07-11 Nipple aspiration fluid yielders and non-yielders: Genetic characteristics
Shidfar A, Wang J, Allu S, Scholtens D, Chatterton R, Khan S. Northwestern University, Chicago, IL.
P3-07-12 Withdrawn
P3-07-13 Evaluation of epidemiological and molecular differences in African American and Caucasian women with triple negative breast cancer
Ellsworth RE, Sturtz LA, Melley J, Means M, Shriver CD. Henry M Jackson Foundation; Windber Research Institute; Walter Reed National Military Medical Center.
   
  Psychosocial, Quality of Life, and Educational Aspects: Survivorship Research
P3-08-01 Cognitive impairment and cortical network dysfunction following chemotherapy
Piccirillo JF, Peelle J, Hardin FM, Nicklaus J, Kallogjeri D, Wilson MB, Schlaggar BL, Coalson R, Shimony J, Bumb C, Ma C. Washington University in STL School of Medicine, St. Louis, MO.
P3-08-02 Breast cancer survivors' outcomes and satisfaction following delivery of a survivorship care plan: Results of a multicenter trial
Stricker CT, Palmer SC, Panzer SL, Syrjala KL, Baker KS, McCabe MS, Rosenstein DL, Partridge AH, Arvey SR, Jacobs LA. Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Fred Hutchinson Cancer Research Center, Seattle, WA; Memorial Sloan-Kettering Cancer Center, New York, NY; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Dana-Farber Cancer Institute, Boston, MA; LIVESTRONG Foundation, Austin, TX.
P3-08-03 Establishing Japanese model "working ring" - Informational, emotional and problem-solving group intervention for working breast cancer survivors
Yamauchi H, Hashimoto K, Iwata T, Hiramatsu R, Fukuda T, Hosaka T. St. Luke's International Hospital, Chu-o-ku, Tokyo, Japan; Travessia, Wakayama, Japan; National Institute of Public Health, Tokyo, Japan.
P3-08-04 Survivorship care involving a nurse-led survivorship consultation, community support and shared care with primary practitioners
Mann GB, Pitcher M, Shanahan K, Storer L, Rio I, Bell B, Hookey S, Hickey M, Kennedy L, Curwen-Walker R, Vij S, Park A, Bell C. Royal Womens Hospital, Parkville, Victoria, Australia; Western Hospital, Sunshine, Victoria, Australia; The Royal Melbourne Hospital, Parkville, Victoria, Australia; BreaCan, Melbourne, Victoria, Australia.
P3-08-05 Chemotherapy-related amenorrhea on adjuvant paclitaxel-trastuzumab (APT trial)
Ruddy KJ, Tolaney SM, Guo H, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Hudis C, Krop IE, Burstein HJ, Winer EP, Partridge AH. Dana-Farber Cancer Institute, Boston, MA; Memorial Sloan-Kettering Cancer Center, New York, NY; Massachusetts General Hospital, Boston, MA; Sarah Cannon Research Institute, Nashville, TN; Duke University Medical Center, Durham, NC; Loyola University Medical Center, Maywood, IL; University of California San Francisco, San Francisco, CA; Washington University, St. Louis, MO; North Shore LIJ Hofstra Medical School, Manhasset, NY; Johns Hopkins Kimmel Cancer Center, Baltimore, MD; University of North Carolina, Chapel Hill, NC.
P3-08-06 ROK study: Breast cancer survivorship cohort in Japan - Characteristics of 2,600 study participants
Mizota Y, Yamamoto S. National Cancer Center, Chuo-ku, Tokyo, Japan.
P3-08-07 Survivorship care planning – When is intervention most effective?
Palmer SC, Stricker CT, Panzer SL, Syrjala KL, Baker KS, McCabe MS, Rosenstein DL, Partridge AH, Arvey SR, Jacobs LA. Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Fred Hutchinson Cancer Research Center, Seattle, WA; Memorial Sloan-Kettering Cancer Center, New York, NY; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Dana-Farber Cancer Institute, Boston, MA; LIVESTRONG Foundation, Austin, TX.
P3-08-08 Pattern of use of an online primary health care information resource for breast cancer survivorship education: The pink ribbon survivors network
Fisher RE, Jensen L, Adams KA. Rocky Mountain Cancer Centers, Boulder, CO; University of Colorado Cancer Center, Aurora, CO.
P3-08-09 Is it me or is it hot in here? Hot flushes (or flashes): An unmet need. UK NCRI breast clinical studies group working party on symptom management (vasomotor)
Morgan A, Fenlon D, Coles C, Armstrong A, Randle K, Thompson A, Dunn J. NCRI Breast Clinical Studies Group, United Kingdom; Faculty of Health Sciences, University of Southampton, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, United Kingdom; The Christie NHS Foundation Trust, Manchester, United Kingdom; University of Dundee, United Kingdom; Independent Cancer Patients' Voice, United Kingdom; University of Warwick, Coventry, United Kingdom.
P3-08-10 Feasibility and promise of a self-directed walking program to reduce joint pain among older breast cancer patients on adjuvant aromatase inhibitors
Nyrop KA, Muss HB, Hackney B, Cleveland R, Callahan LF. University of North Carolina at Chapel Hill, Chapel Hill, NC.
P3-08-11 Pregnancy after breast cancer and recurrence risk
Preusse C, Gammill H, McDougall J, Ma K, Gooley T, Li C, Gadi V. Fred Hutchinson Cancer Research Center, Seattle, WA; University of Washington, Seattle, WA.
P3-08-12 Influence of a clinic-based survivorship intervention on dietary change and lifestyle recommendations among Hispanic and non-Hispanic women following adjuvant therapy for breast cancer
Greenlee H, Awad D, Crew KD, Kalinsky K, Maurer M, Brafman L, Jayasena R, Tsai WY, Neugut AI, Hershman DL. Columbia University Medical Center, New York, NY.
P3-08-13 Short-term impact of a breast cancer survivorship clinic in a public hospital setting
Viveros LA, Feldman NR, Hemmelgarn M, Zibecchi LT, Gibbons MM. UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA; Olive View-UCLA Medical Center, Sylmar, CA.
P3-08-14 Could the preoperative systemic therapy be a risk factor for breast cancer-related lymphedema in stage II/III breast cancer?
Jung SY, Song EJ, You JY, Lee MH, Kwon Y, Ko KL, Park IH, Lee KS, Ro J, Lee S, Kang H-S, Lee E, Shin KH. National Cancer Center, Goyang, Republic of Korea.
P3-08-15 Improving survivors' quality of care through use of self-reported satisfaction data
Palos GR, Zandstra F, Bevers T, Gilmore K, Greer M, Rodriguez MA. The University of Texas MD Anderson Cancer Center, Houston, TX.
P3-08-16 Strengthening bridges: A navigation plan for survivors of breast and gynecological cancers in the Georgia Cancer Center for excellence at Grady Health
Senior-Crosby D, Thompson WW, Haardörfer R, Trim L. Emory University, Atlanta, GA; Emory University-Rollins School of Public Health Behavioral Sciences & Health Education, Atlanta, GA.
P3-08-17 Objectively measured physical activity in breast cancer survivors
Soria A, Pagola I, Ortega MJ, Brea L, Fiuza C, Cebolla H, Palomo I, Montil M, Malón D, Guerra J, Lucia A, Ruiz A. Hospital Universitario Fuenlabrada, Fuenlabrada, Madrid, Spain; Universidad Europea de Madrid, Spain; Universidad Nacional de Educación a Distancia, Spain; Hospital Universitario Puerta de Hierro, Spain.
P3-08-18 Association of tamoxifen use and ovarian aging in patients with invasive or pre-invasive breast cancer
Chien AJ, Duralde E, Kao C-N, McCulloch C, Melisko M, Rugo HS, Cedars M, Goldman M, Rosen M. University of California, San Francisco, San Francisco, CA.
   
  Psychosocial, Quality of Life, and Educational Aspects: Quality of Life - Supportive Care
P3-09-01 NEPA, a fixed-dose combination of netupitant and palonosetron, prevents chemotherapy-induced nausea and vomiting (CINV) more effectively and reduces the impact on daily living for breast cancer patients compared with palonosetron
Rugo HS, Rossi G, Rizzi G, Borroni ME, Lorusso V, Karthaus M, Bondarenko I, Sarosiek TJ, Aapro MS. University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Helsinn Healthcare SA, Lugano, Switzerland; National Cancer Institute Giovanni Paolo II, Bari, Italy; Hematology & Oncology, Staedt. Klinikum Neuperlach and Harlaching, Munich, Germany; Dnipropetrovsk Medical Academy, Dnipropetrovsk, Ukraine; NZOZ Magodent, Warsaw, Poland; Institut Multidisciplinaire d'Oncologie, Genolier, Switzerland.
P3-09-02 Optimal anti-emetic choice for breast cancer patients receiving anthracycline and cyclophosphamide-based chemotherapy – A systematic review and network meta-analysis of randomized controlled trials
Ng TL, Clemons M, Kuchuk I, Roscoe J, Hutton B. University of Ottawa, Ottawa, ON, Canada; Ottawa Hospital Research Institute, Ottawa, ON, Canada; University of Rochester Medical Center, Rochester, NY.
P3-09-03 Final result of randomised controlled phase II study of the efficiency of palonosetron, aprepitant, and dexamethasone for day1 with or without dexamethasone on days 2 and 3
Kosaka Y, Sengoku N, Minatani N, Kikuchi M, Nishimiya H, Waraya M, Enomoto T, Kuranami M, Tanino H, Watanabe M. Kitasato University School of Medicine, Sagamihara, Japan.
P3-09-04 Adherence to the guidelines for prophylaxis of chemotherapy-induced nausea and vomiting
Koh S-J, Oh S. Ulsan University Hospital, Ulsan, Korea; Dong-A University Hospital, Busan, Korea.
P3-09-05 Febrile neutropenia in FEC-D regimen for early stage breast cancer, is there a place for G-CSF primary prophylaxis?
Miguel I, Wincler P, Sousa M, Cardoso C, Moreira A, Brito M. Portuguese Cancer Institute Francisco Gentil Lisbon, Lisbon, Portugal.
P3-09-06 Development and validation of a questionnaire for axillary web syndrome self-assessment
Nevola Teixeira LF, Sandrin F, Rietjens M, Veronesi P, Lohsiriwat V, Casales Schorr M, Simoncini MC, Gandini S, Zanatta Sarian LO, Luini A. European Institute of Oncology, Milano, MI, Italy; Mahidol University School of Medicine, Bangkoknoi, Bangkok, Thailand; Universidade Federal de Ciencias da Saude de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil; University of Campinas, Campinas, Brazil.
P3-09-07 Construction of two quality of life questionnaires from young breast cancer patients and their partner
Vanlemmens L, Congard A, Antoine P, Fournier E, Lesur A, Loustalot C, Guillemet C, Leclercq M, Levy C, Giraud C, Lefeuvre-Plesse C, Frenel J-S, Simon H, Leroy T, Becuwe C, De Cordoue S, Ferrero J-M, Nierges D, Tiberghien S, Grosjean J, Prulhiere K, Chossiere L, Duprez C, Christophe V. Centre Oscar Lambret, Lille, France; Université Charles-de-Gaulle - Lille 3, Lille, France; Centre Alexis-Vautrin, Vandœuvre-lès-Nancy, France; Centre Georges-François Leclerc, Dijon, France; Centre Henri Becquerel, Rouen, France; Cabinet Gynecologique, Marcq En Baroeul, France; Centre François Baclesse, Caen, France; Pôle Médical d'Imagerie et de Cancérologie du Pont Saint Vaast, Douai, France; Centre Eugène Marquis, Rennes, France; Centre René Gauducheau, Nantes, France; CHRU, Brest, France; Centre Bourgogne, Lille, France; Centre Antoine Lacassagne, Nice, France; Hôpitaux Privés de Metz, Metz, France; Clinique des Dentellières, Valenciennes, France; Institut du Cancer Courlancy Reims, Reims, France; Centre Hospitalier, Dunkerque, France; Clinique la Victoire, Tourcoing, France; Clinique Gray, Maubeuge, France; Université de Provence, Marseille, France; Centre d Oncologie Gentilly, Nancy, France.
P3-09-08 Withdrawn
P3-09-09 Comparison of multi-frequency bioimpedance with perometry for the early detection of lymphoedema after axillary node clearance
Bundred NJ, Stockton C, Fellows K, Keeley V, Riches K, Ashcroft L, Purushotham A, Bramley M, Hodgkiss T, BEA Investigators. University Hospital of South Manchester, Manchester, United Kingdom; Derby Hospitals NHS Foundation Trust, Derby, United Kingdom; The Christie Hospital NHS Foundation Trust, Manchester, United Kingdom; Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom; The Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom.
P3-09-10 Adapted physical activity effect on aerobic function in patients with breast cancer treated with adjuvant or neoadjuvant chemotherapy
Cornette T, Vincent F, Antonini M-T, Leobon S, Venat L, Lavau-Denes S, Tubiana-Mathieu N. University Hospital, Limoges, France; Faculty of Medicine, EA3842, Limoges University, Limoges, France.
P3-09-11 Acupuncture for the treatment of lymphedema in breast cancer patients: A pilot study in Korean women
Jeong YJ, Kim MS, Jang JI, Bong JG, Park SH, Kwon HJ, Park YS, Kwon OC, Shin IH. College of Medicine, Catholic University of Daegu, Daegu, Korea; Daegu Oriental Hospital of Daegu Haany University, Daegu, Korea; Daegu Haany University Oriental Medicine, Daegu, Korea; East-West Medical Center, Daegu Catholic University Medical Center, Daegu, Korea; School of Medicine, Catholic University of Daegu, Daegu, Korea.
P3-09-12 Effects of acupuncture on rehabilitation after breast cancer surgery - Preliminary results
Nazario AP, Giron PS, Simão CA, Facina G. São Paulo Federal University, São Paulo, Brazil.
P3-09-13 Assessment of muscle strenght and range of motion of shoulder women undergoing surgery for breast cancer
Nazário A, Simão C, Facina G. Federal University of Sao Paulo, Sao Paulo, Brazil.
P3-09-14 Using lean methods to increase access to support services in younger breast cancer survivors
Mayer DK, Kinley T, Gerstel A, Jackson M, Shea T, Donald RL, Lawrence MB. UNC Lineberger Cancer Center, Chapel Hill, NC.
P3-09-15 Permanent chemotherapy induced alopecia in early breast cancer patients after (neo)adjuvant chemotherapy: Long term follow up
Bertrand M, Mailliez A, Vercambre S, Kotecki N, Mortier L, Bonneterre J. Hopital Duchenne, Boulogne sur Mer, France; Centre Oscar Lambret, Lille, France; Clinique de Dermatologie - CHRU, Lille, France; Universite Lille Nord de France, Lille, France.
P3-09-16 Improved quality of life for early stage breast cancer survivors on a low carbohydrate, calorie restricted dietary intervention
Krie AK, Demuth HM, Hu Y, Ageton C, Bohlen KN, Norfolk D, Thomes R, Muth J, Fahrendorf A, Kittelsrud J, Rojas-Espaillat LA, Davies GE. Avera Cancer Institute, Sioux Falls, SD; Avera Research Institute, Sioux Falls, SD; University of South Dakota, Sioux Falls, SD.
P3-09-17 One year of adjuvant hormone therapy does not increase patient fatigue: Results of a prospective early stage breast cancer trial
Lower EE, Kennedy D, Adams P. University of Cincinnati Medical Center, Cincinnati, OH.
P3-09-18 A pilot study of medical Qi Gong in breast cancer patients with menopausal symptoms
Malensek AM, Nixon DW, Quan W, Lam S, Wascher R, Campbell J. Cancer Treatment Centers of America at Western Regional Medical Center, Goodyear, AZ; Zen Wellness, Avondale, AZ.
P3-09-19 A prospective study of fertility preservation by controlled ovarian hyperstimulation (COH) without letrozole in young breast cancer patients before adjuvant chemotherapy: Preliminary results
Mailliez A, Vendel Y, Govaere A, Jebert S, Bonneterre J, Decanter C. Centre Oscar Lambret, Lille, France; Centre Hospitliaer Universitaire de Lille, Lille, France.
   
  Psychosocial, Quality of Life, and Educational Aspects: Palliation and Support - Pain Management
P3-10-01 Burden of symptoms associated with development of metastatic bone disease in patients with breast cancer
Cleeland C, von Moos R, Walker M, Wang Y, Gao J, Liede A, Arellano J, Balakumaran A, Qian Y. University of Texas MD Anderson Cancer Center, Houston, TX; Kantonsspital Graubünden, Chur, Switzerland; ACORN Research LLC, Memphis, TN; IMS Health, Plymouth Meeting, PA; Amgen Inc., Thousand Oaks, CA.
P3-10-02 The BOMET-QOL questionnaire in patients with breast cancer and bone metastasis: The prospective MABOMET study from the Spanish breast cancer research group (GEICAM)
Del Barco S, Muñoz M, Margeli M, Chacon JI, Cassinello J, Antolin S, Adrover E, Ramos-Vazquez M, Carrasco E, Jimeno MA, Ojeda B, Gonzalez X, Gonzalez S, Constenla M, Florian J, Miguel A, Llombart A, Lluch A, Ruiz-Borrego M, Colomer R, Barnadas A. Hospital U. Josep Trueta, Gerona, Spain; Hospital Clinic i Provinical, Barcelona, Spain; Hospital Germans Trias i Pujol, Barcelona, Spain; Hospital Virgen de la Salud, Toledo, Spain; Hospital General de Guadalajara, Guadalajara; Complejo Hospitalario U. A Coruña, A Coruna, Spain; Complejo Hospitalario Universitario de Albacete, Albacete, Spain; Centro Oncologico de Galicia, A Coruna, Spain; GEICAM (Spanish Breast Cancer Research Group), Madrid, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Mutua de Terrassa, Barcelona, Spain; Complejo Hospitalario De Pontevedra, Pontevedra, Spain; Hospital Comarcal de Barbastro, Huesca, Spain; Hospital Althaia Manresa, Barcelona, Spain; Hospital Arnau de Vilanova, Valencia, Spain; Hospital Clinico de Valencia, Valencia, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Hospital Universitario La Princesa, Madrid, Spain.
P3-10-03 A simple intervention to relieve chronic neuropathic post-mastectomy pain
Tang CJ, Eder SE, Lee DJ, Rabow MW, Esserman LJ. University of California San Francisco, San Francisco, CA.
P3-10-04 Prevalence of pain and barriers to pain management in breast cancer survivors in Vietnam
Nguyen J, Tran TT, Ta TV, Ginsburg O. University of Toronto, Toronto, ON, Canada; Women's College Research Institute, Toronto, ON, Canada; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada; National Cancer Institute, Hanoi, Viet Nam.
   
  Psychosocial, Quality of Life, and Educational Aspects: Psychosocial Aspects
P3-11-01 Prospective study of cognitive function in women with early stage breast cancer: Predictors of cognitive decline and relationship to cognitive complaints
Heflin LH, Fang S, DeLuca A, Melisko MM, Moasser M, Park JW, Chien AJ, Munster P, Landau SM, Kramer JH, Jagust WJ, Rugo HS. New Mexico Highlands University, Las Vegas, NM; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of California Berkeley School of Public Health, Berkeley, CA; University of California San Francisco, San Francisco, CA.
P3-11-02 Women with pregnancy-associated early breast cancer achieve improved emotional well-being as a result of their cancer experience
Murthy RK, Schover LR, Theriault RL, Valero V, Woodard TL, Hodge S, Litton JK. University of Texas MD Anderson Cancer Center, Houston, TX.
P3-11-03 Withdrawn
P3-11-04 The effect of group intervention therapy for young breast cancer patients under 35 years old
Kitano A, Hosaka T, Iwata T, Osaka W, Kitagawa H, Ohde S, Yamauchi H. St Luke's International Hospital, Tokyo, Japan; St Luke's Nursing College, Tokyo, Japan; St. Luke's Life Science Institute Center for Clinical Epidemiology, Tokyo, Japan.
   
  Treatment: Adjuvant Chemotherapy
P3-12-01 Withdrawn
P3-12-02 Withdrawn
P3-12-03 Adjuvant capecitabine in breast cancer patients with pathologic residual disease after neoadjuvant chemotherapy: First safety analysis of CREATE-X (JBCRG-04)
Ohtani S, Masuda N, Im Y-H, Im S-A, Park B-W, Kim S-B, Yanagita Y, Takao S, Ohno S, Aogi K, Iwata H, Yoshidome K, Nishimura R, Ohashi Y, Lee S-J, Toi M. Hiroshima City Hospital, Hiroshima, Japan; National Hospital Organization Osaka National Hospital, Osaka, Japan; Samsung Medical Center, Seoul, Korea; Seoul National University Hospital, Seoul, Korea; Yonsei University Severance Hospital, Seoul, Korea; Asan Medical Center, Seoul, Korea; Gunma Prefectural Cancer Center, Gunma, Japan; Hyogo Cancer Center, Hyogo, Japan; National Kyusyu Cancer Center, Fukuoka, Japan; National Hospital Organizaton Shikoku Cancer Center, Ehime, Japan; Aichi Cancer Center, Aichi, Japan; Osaka Police Hospital, Osaka, Japan; Kumamoto Municipal Hospital, Kumamoto, Japan; Tokyo University, Tokyo, Japan; Yeungnam University Hospital, Daegu, Korea; Kyoto University Hospital, Kyoto, Japan.
P3-12-04 Withdrawn
P3-12-05 The BC provincial experience on FEC-D vs. AC-taxane protocol as adjuvant treatment for breast cancer
Cossetti RD, Tyldesley S, Speers C, Gelmon KA. BCCA, Vancouver, BC, Canada.
P3-12-06 Statin use and outcome among breast cancer patients treated with neoadjuvant systemic chemotherapy
Chavez-Mac Gregor M, Lei X, Litton JK, Melhem-Bertrand A, Giordano SH, Masuda H, Ueno N, Gabriel HN, Valero V. UT MD Anderson Cancer Center, Houston, TX.
P3-12-07 Dose delays, dose reductions, and relative dose intensity in early stage breast cancer patients receiving (neo)adjuvant chemotherapy in community oncology practices
Favret AM, Li X, Denduluri N, Morrow PK, Bhor M, Barron RL, Dhanda R, Langeberg WJ, Saravanan S, Girardi V, Lyman GH. Virginia Cancer Specialists PC and The US Oncology Network, Fairfax, VA; Amgen Inc., Thousand Oaks, CA; Virginia Cancer Specialists PC and The US Oncology Network, Arlington, VA; McKesson Specialty Health, The Woodlands, TX; Duke University School of Medicine and the Duke Cancer Institute, Durham, NC.
P3-12-08 Venous thromboembolism in patients receiving chemotherapy for breast cancer
Plant RE, Walter HS, Ahmed SI. Leicester Royal Infirmary, Leicester, United Kingdom.
P3-12-09 The prevalence and quantity of circulating tumor cells (CTCs) after adjuvant chemotherapy with and without anthracyclines in patients with HER2-negative early breast cancer (EBC)
Schochter F, Andergassen U, Neugebauer JK, Friedl TWP, Pestka A, Jueckstock JK, Jaeger B, Salmen JC, Hepp PGM, Heinrich G, Camara O, Decker T, Ober A, Fehm TN, Pantel K, Fasching PA, Schneeweis A, Beckmann MW, Janni W, Rack BK. University of Ulm, Ulm, Germany; Ludwig-Maximilians-University, Munich, Germany; Heinrich Heine University, Duesseldorf, Germany; Medical Office of Gynecology, Fürstenwalde, Germany; Jena University Hospital, Jena, Germany; Medical Office of Oncology, Ravensburg, Germany; St. Vincenz Hospital Limburg, Limburg, Germany; Institute of Tumor Biology, University Medical CenterHambur-Eppendorf, Hamburg, Germany; University Erlangen, Erlangen, Germany; National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany.
P3-12-10 Feasibility of four cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: A Wisconsin oncology network study
Wisinski KB, Burkard ME, Njiaju U, Donohue S, Hegeman R, Stella A, Mansky P, Shah V, Goggins T, Qamar R, Dietrich L, Kim K, Traynor A, Tevaarwerk A. University of Wisconsin Carbone Cancer Center, Madison, WI; Bellin Memorial Hospital, Green Bay, WI; Columbia St. Mary's, Milwaukee, WI; Fox Valley Hematology and Oncology, Appleton, WI; Aurora Cancer Care, Wauwatosa, WI; Gunderson Lutheran Health System, Lacrosse, WI.
P3-12-11 Provincial variation in utilization of adjuvant chemotherapy regimens in early stage breast cancer: Data from the cancer care Ontario new drug funding program (NDFP)
Eisen A, Srikanthan A, Yeung L, Iyer R, Trudeau M. Odette Cancer Centre; University of Toronto; Cancer Care Ontario.
P3-12-12 Body mass index does not influence febrile neutropenia and delivered dose intensity in adjuvant chemotherapy for breast cancer
Mayr D, Hochreiner G, Fuchs D, Fridrik MA. Internal Medicine 3, General Hospital Linz, Linz, Austria; General Hospital Linz, Linz, Austria.
P3-12-13 First analysis of ASTER study AT for 3 cycles followed by CMF for 3 cycles as neo or adjuvant chemotherapy in early stage breast cancer. A single institution experience
Mariani G, Galli G, Mariani P, Bianchi GV, Capri G, Cresta S, Damian S, De Benedictis E, Valagussa P, Magazzu' D, De Braud FG, Moliterni A. Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Fondazione Michelangelo, Milan, Italy.
   
  Treatment: Advanced Chemotherapy
P3-13-01 Primary efficacy endpoint analysis of the CARIN trial: Capecitabine (Cap) and bevacizumab (Bev) with or without vinorelbine (Vin) in first line metastatic breast cancer (MBC)
Welt A, Lerchenmüller C, Decker T, Marschner N, Salat C, Hegewisch-Becker S. West German Cancer Center, University Hospital, Essen, Germany; Onkologische Schwerpunktpraxis, Münster, Germany; Onkologische Schwerpunktpraxis, Ravensburg, Germany; Onkologische Schwerpunktpraxis, Freiburg, Germany; Onkologische Schwerpunktpraxis, München, Germany; Onkologische Schwerpunktpraxis, Hamburg, Germany.
P3-13-02 Comparison of docetaxel and capecitabine (TX) and vinorelbine and capecitabine (NX) for treatment of metastatic breast cancer failed to anthracyclines
Zhang S, Jiang Z, Jiang L, Yang J, Song Y, Wang X, Ouyang Q, Hu X, Wang T. Affiliated Hospital of Military Medical Science Academy of the PLA, Beijing, China; General Hospital of PLA, Beijing, China; Affiliated Hospital of Qingdao Medical College, Qingdao, Shandong, China; The Cancer Hospital of Zhejiang Province, Hangzhou, Zhejiang, China; The Cancer Hospital of Hunan Province, Changsha, Hunan, China; Cancer Hospital of Fudan University, Shanghai, China.
P3-13-03 A phase III, open-label, randomized study of eribulin versus capecitabine in patients (pts) with metastatic breast cancer (MBC): Effect of post-progression anti-cancer treatments (PPT) and metastatic progression events on overall survival
Awada A, Kaufman PA, Yelle L, Cortes J, Wanders J, O'Shaughnessy J, Olivo MS, He Y, Garzon F, Dutcus CE, Binder TA, Twelves C, Perez EA. Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH; University of Montreal, Montreal, Quebec, QC, Canada; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Formerly of Eisai Ltd, Hatfield, Hertfordshire, United Kingdom; Charles A. Sammons Cancer Center, Texas Oncology, and US Oncology, Dallas, TX; Eisai Inc., Woodcliff Lake, NJ; Institute of Cancer Studies & Pathology, and St James's Institute of Oncology, St James's University Hospital, Leeds, United Kingdom; Mayo Clinic, Jacksonville, FL.
P3-13-04 Effect of age on tolerability and efficacy of eribulin and capecitabine in patients with metastatic breast cancer treated in study 301
Kaufman PA, Yelle L, Cortes J, Perez EA, Awada A, Wanders J, Olivo MS, He Y, Dutcus CE, Twelves C. Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH; University of Montreal, Montreal, QC, Canada; Vall D'Hebron University Institute of Oncology, Barcelona, Spain; Mayo Clinic, Jacksonville, FL; Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium; Formerly of Eisai Ltd, Hatfield, Hertfordshire, United Kingdom; Eisai Inc., Woodcliff Lake, NJ; Leeds Institute of Cancer Studies and Pathology, and St James's Institute of Oncology, Leeds, United Kingdom.
P3-13-05 Eribulin mesylate as first-line therapy for locally recurrent or metastatic HER2-negative breast cancer: Results of a phase 2, multicenter, single-arm study
McIntyre K, O'Shaughnessy J, Schwartzberg L, Glück S, Berrak E, Song J, Rege J, Cox D, Vahdat L. Texas Oncology-Dallas Presbyterian Hospital US Oncology, Dallas, TX; Texas Oncology Baylor-Charles A. Sammons Cancer Center US Oncology, Dallas, TX; The West Clinic, Memphis, TN; Sylvester Comprehensive Cancer Center University of Miami, Leonard M. Miller School of Medicine, Miami, FL; Eisai Inc, Woodcliff Lake, NJ; Weill Cornell Medical College, New York, NY.
P3-13-06 A prospective phase II trial of vinorelbine plus oxaliplatin in second- or third-line metastatic triple-negative breast cancer
Wang Z, Zhang J, Wang L, Hu X, Wang B, Cao J, Lv F, Zhen C, Zhang S, Shao Z. Fudan University Shanghai Cancer Center, Shanghai, China.
P3-13-07 A-TaXel: Multicenter phase II combination of bevacizumab (A) with weekly paclitaxel (Ta) and capecitabine (Xel) in first line treatment for patients with triple negative metastatic or locally advanced breast cancer (TNMBC), a GINECO study
Ferrero J-M, Hardy-Bessard A-C, Capitain O, Lortholary A, Salles B, Follana P, Herve R, Deblock M, Dauba J, Atlassi M, Largillier R. Centre Antoine Lacassagne, Nice, France, Metropolitan; Clinique Armoricaine de Radiologie, Saint-Brieuc, France; ICO Paul Papin, Angers, France; Centre Catherine de Sienne, Nantes, France; Centre Hospitalier William Morey, Chalon-sur-Saône, France; Hôpital Privé Clairval, Marseille, France; ICL Institut de Cancérologie de Lorraine, Vandoeuvre-les-Nancy, France; Centre Hospitalier de Mont-de-Marsan, Mont-de-Marsan, France; Centre Hospitalier du Mans, Le Mans, France; Centre Azuréen de Cancérologie, Mougins, France.
P3-13-08 A phase I study of weekly nab-paclitaxel in combination with S-1 in patients with metastatic breast cancer
Kuroi K, Tsurutani J, Yamashita T, Aruga T, Shigekawa T, Miyazaki M, Nishina S, Makimura C, Tanizaki J, Okamoto K, Iwasa T, Komoike Y, Nakagawa K, Saeki T. Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan; Kinki University Faculty of Medicine, Osaka, Japan; Saitama Medical University International Medical Center, Saitama, Japan.
P3-13-09 Relative dose intensity of taxane-based chemotherapy in patients with stage IV breast cancer
Denduluri N, Havrilesky L, Bhor M, Bhowmik D, Morrow PK, Watson H, Dhanda R, Li X, Chung H, Saravanan S, Barron R, Crawford J. Virginia Cancer Specialists PC and the US Oncology Network, Arlington, VA; Duke University Medical Center and Duke Cancer Institute, Durham, NC; McKesson Specialty Health, The Woodlands, TX; Amgen Inc., Thousand Oaks, CA.
P3-13-10 Treatment patterns and benefit of later lines of chemotherapy in metastatic breast cancer: A retrospective cohort study
Lindman H, Svanström C, Lidbrink E. Uppsala University Hospital, Uppsala, Sweden; Karolinska Institute, Stockholm, Sweden; Radiumhemmet, Karolinska Solna, Stockholm, Sweden.
P3-13-11 Unexpected large treatment and outcome variations in metastatic breast cancer: Results of a hormone receptor positive cohort study in the Netherlands
Tjan-Heijnen VCG, Lobbezoo DJA, van Kampen RJW, Voogd AC, Dercksen M, van den Berkmortel F, Smilde TJ, van de Wouw AJ, Peters FPJ, van Riel JMGH, Peters NAJB, de Boer M, Peer PGM. Maastricht University Medical Center, Maastricht, Netherlands; Máxima Medical Center, Eindhoven, Netherlands; Atrium Medical Center Parkstad, Heerlen, Netherlands; Jeroen Bosch Hospital, Den Bosch, Netherlands; VieCuri Medical Center, Venlo, Netherlands; Orbis Medical Center, Sittard, Netherlands; Sint Elisabeth Hospital, Tilburg, Netherlands; Sint Jans Hospital, Weert, Netherlands; Radboud University Nijmegen Medical Center, Nijmegen, Netherlands.
   
  Treatment: Neoadjuvant Chemotherapy
P3-14-01 Features of neoadjuvant and adjuvant chemotherapy in breast cancer – A population-based study on 39404 patients
von Minckwitz G, Kern P, Schneeweiss A, Gluz O, Harbeck N, Neumann M, Badiian M, Fries H, Rezai M. German Breast Group, Neu-Isenburg, Germany; Univ. Women's Hospital, Frankfurt, Germany; Breast Center Düsseldorf Luisenkrankenhaus, Düsseldorf, Germany; University Hospital of Essen, Germany; Universitätsklinikum Heidelberg, Germany; West German Study Group, Monchengladbach, Germany; Universität München, Germany; Universitätsklinikum Düsseldorf, Germany.
P3-14-02 Patterns of the use of primary systemic therapy in the United States
Mougalian SS, Abu-Khalaf MM, Sanft T, Hofstatter E, DiGiovanna M, Chung G, Lannin D, Killelea B, Pusztai L, Chagpar AB. Yale Cancer Center, New Haven, CT.
P3-14-03 Pathological complete response after primary chemotherapy as a surrogate end point of treatment efficacy in breast cancer patients: A trial-based meta-analysis
Amoroso V, Berruti A, Gallo F, Bertaglia V, Paloja E, Simoncini EL, Generali D, Bottini A, Bruzzi P, Sormani MP. University of Brescia and Spedali Civili of Brescia, Brescia, Italy; University of Genoa, Genoa, Italy; University of Turin, San Luigi Hospital, Orbassano, Italy; Istituti Ospitalieri of Cremona, Cremona, Italy.
P3-14-04 The choice of the indicator lesion impacts on the pCR rate – An analysis of 114 bilateral breast cancer patients treated within neoadjuvant trials
Loibl S, Mergler B, Eppel A, Solbach C, Lübbe KM, Eidtmann H, Rezai M, Hanusch C, Fehm T, Bartzke G, Burgmann D-M, Krabisch P, Untch M, Nekljudova V, von Minckwitz G. German Breast Group, Neu-Isenburg; Universität Mainz; Brustzentrum Universität Mainz; Henriettenstiftung, Düsseldorf; Luisenkrankenhaus Düsseldorf; Rotkreuzklinikum München gGmbH, Frauenklinik, München; Universitätsfrauenklinik Düsseldorf; Helios Kliniken Berlin; Universitätsfrauenklinik München; Klinik für Frauenheilkunde und Geburtshilfe, Chemnitz; Universitätsfrauenklinik Frankfurt.
P3-14-05 Randomized phase II study of preoperative docetaxel and cyclophosphamide-containing chemotherapy for luminal-type breast cancer
Sato N, Masuda N, Higaki K, Morimoto T, Yanagita Y, Mizutani M, Ohtani S, Kaneko K, Fujisawa T, Takahashi M, Kadoya T, Matsunami N, Yamamoto Y, Ohno S, Takano T, Morita S, Tanaka S, Toi M. Niigata Cancer Center Hopital; National Hospital Organization Osaka National Hospital; Hiroshima City Hospital; Yao Municipal Hospital; Gunma Prefectural Cancer Center; National Hospital Organization Hokkaiodo Cancer Center; Hiroshima University Hospital; Osaka Rosai Hospital; Kumamoto University Hospital; National Kyusyu Cancer Center; Toranomon Hospital; Kyoto University Hospital.
P3-14-06 Residual tumor autophagy marker LC3B is a prognostic marker in local advanced breast cancer underwent neoadjuvant chemotherapy
Chen S, Jiang Y-Z, Huang L, Liu Y, Yu K-D. Fudan University Shanghai Cancer Center/Cancer Institute, Shanghai, China. Sheng Chen is a recipient of an Avon-AACR International Scholar-In-Training Award
P3-14-07 Carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for triple-negative breast cancer - A phase II clinical trial
Zhang P, Yin Y, Xu B, Wang X, Zhang B, Li Q, Yuan P, Wang J, Cai R, Ma F, Fan Y, Xu X. Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China.
P3-14-08 A randomized phase II trial comparing docetaxel plus cyclophosphamide with epirubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy for hormone receptor-negative breast cancer. Kanagawa breast oncology group (KBOG) 1101 study
Ishikawa T, Shimizu D, Tanabe M, S. Oba M, Sasaki T, Morita S, Kida K, Nawata S, Mogami M, Doi T, Tsugawa K, Ogata H, Kosaka Y, Sengoku N, Saito Y, Suzuki Y, Suto A, Chishima T, Ichikawa Y, Endo I, Tokuda Y. Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan.
P3-14-09 Should testing for estrogen receptor, progesterone receptor and HER2 be repeated following neoadjuvant chemotherapy?
Shaaban AM, Gahlut R, Fatayer H, Dodwell D, Velikova G, Perren T, Dall BJ, Sharma N, Lansdown M. St James's University Hospital, Leeds, United Kingdom.
P3-14-10 Conversion to node-negative after neoadjuvant chemotherapy is a surrogate prognostic marker in patients with hormone receptor-positive breast cancer
Takahashi Y, Hayashi N, Matsuda N, Kajiura Y, Yoshida A, Yagata H, Nakamura S, Suzuki K, Tsunoda H, Yamauchi H. St. Luke's International Hospital, Tokyo, Japan; Showa University School of Medicine, Tokyo, Japan.
P3-14-11 Microarray data analysis and long term outcomes of NCIC-CTG MA.22: Neoadjuvant epirubicin and docetaxel with pegfilgrastim support for locally advanced breast cancer
Trudeau M, Chapman J-A, Guo B, Clemons M, Dent R, Jong R, Kahn H, Shepherd L, Pritchard K, Xu J, O'Brien P, Parissenti A. Sunnybrook Health Sciences Centre, Toronto, ON, Canada; NCIC Clinical Trials Group, Kingston, ON, Canada; The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada; Advanced Medical Research Institute of Canada (AMRIC), Sudbury, ON, Canada.
P3-14-12 Risk factors for local regional recurrence in patients undergoing breast conserving surgery following neoadjuvant chemotherapy and validation of the MD Anderson prognostic index
Alvarado M, Mukhtar R, Hwang J, Rounds K. University of California San Francisco, San Francisco, CA.
P3-14-13 eIF4E/4EBP1 axis and response to neoadjuvant trastuzumab-based treatment in HER2+ breast cancer – Results of a multicentre French retrospective cohort
Dalenc F, Le Guellec S, Arnould L, Coudert B, Vagner S, Bachelot T, Treilleux I, Debled M, MacGrogan G, Jacot W, Bibeau F, Vanlemmens L, André F, Mathieu M-C, Augereau P, Verriele V, Penault-Llorca F, Lacroix-Triki M, Filleron T. Institut Claudius Regaud, Toulouse, France; Centre GF Leclerc, Dijon, France; Institut Curie, Orsay, France; Centre Léon Bérard, Lyon, France; Institut Bergonié, Bordeaux, France; Centre Val d'Aurelle-ICM, Montpellier, France; Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Paul Papin, Angers, France; Centre Jean Perrin, Clermont-Ferrand, France.
P3-14-14 Neoadjuvant phase II trial with carboplatin and eribulin in triple negative breast cancer patients
Giordano SB, Jeruss JS, Bethke KP, Hansen NM, Khan S, Von Roenn J, Rosen S, Gradishar WL, Siziopikou KP, Meservey C, Kaklamani V. Northwestern University, Chicago, IL.
P3-14-15 Nabrax: Neoadjuvant therapy of breast cancer with weekly nab-paclitaxel: Final safety of GEICAM 2011-02
Martin M, Antolin S, Anton A, Plazaola A, Garcia-Martinez E, Segui MA, Sanchez-Rovira P, Esteban C, Garcia-Valdes E, Calvo L, Quindos M, Carrasco E, Rodriguez-Martin C, Chacon JI. Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; Complejo Hospitalario de la Coruña, La Coruña, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Onkologikoa, San Sebastian, Spain; Hospital General Universitario Morales Messeguer, Murcia, Spain; Corporacion Sanitaria Parc Taulí, Barcelona, Spain; Complejo Hospitalario de Jaén, Jaen, Spain; GEICAM (Spanish Breast Cancer Research Group), Madrid, Spain; Hospital Universitario Virgen de la Salud, Toledo, Spain.
P3-14-16 A phase 2 trial of myocet®, cyclophosphamide +/- trastuzumab followed by weekly paclitaxel +/- trastuzumab as primary systemic therapy in operable and locally advanced breast cancer
Pistilli B, Rossi D, Benedetti G, Baldelli AM, Decembrini-Cognigni P, Casadei V, Ciccioli G, Ranaldi R, Fiorentini G, Latini L. Oncology Unit-Area Vasta 3, Macerata, MC, Italy; Ospedali Riuniti Marche Nord, Pesaro, PU, Italy; Surgery Unit-Area Vasta 3, Civitanova Marche, MC, Italy; Radiology Unit-Area Vasta 3, Macerata, MC, Italy; Pathology Unit-Area Vasta 3, Macerata, MC, Italy.
P3-14-17 Results of a novel neoadjuvant chemotherapy (NAC) for breast cancer
Rivera-Rodriguez N, Cabanillas F, Lawrenson L, Negron V, Pavia O, Bruno M, Echenique M, Pardo W, Santiago K. Auxilio Cancer Center, San Juan, PR.
P3-14-18 Dose-dense neoadjuvant chemotherapy in locally advanced breast cancer. Long term results of a cooperative retrospective study
Ionta MT, Notari F, Murgioni S, Cugudda S, Marongiu M, Solinas C, Pala L, Lepori S, Demurtas L, Olmeo N, Valle E, Sarobba G, Frau B, Pusceddu V, Defraia S, Serci C, Fanzecco M, Tanca FM, Atzori F. Hospital-University, Cagliari, Italy; SS Annunziata Hospital, Sassari, Italy; Businco Hospital, Cagliari, Italy; Hospital-University, Sassari, Italy; Department of Medical Science University, Cagliari, Italy.
P3-14-19 Panitumumab in combination with FEC 100 (5-fluorouracil, epirubicin, cyclophosphamide) followed by docetaxel for operable, triple negative breast cancer (TNBC): Patient outcome
Penault-Llorca F, Radosevic-Robin N, Abrial C, Dauplat M-M, Weber B, Mouret-Reynier M-A, Gligorov J, Tredan O, Privat M, Uhrhammer N, Desrichard A, Bidet Y, Cayre A, Aube C, Romero P, Kwiatkowski F, Chalabi N, Bignon Y-J, Chollet P, Nabholtz J-M. Jean Perrin Comprehensive Cancer Centre and ERTICA EA 4677 Research Team, University of Auvergne, Clermont-Ferrand, France; Alexis Vautrin Comprehensive Cancer Centre, Vandoeuvre les Nancy, France; Tenon University Hospital, Paris, France; Leon Berard Comprehensive Cancer Centre, Lyon, France; Jean Perrin Comprehensive Cancer Centre, Clermont-Ferrand, France; Jean Perrin Comprehensive Cancer Centre, INSERM UMR990, University of Auvergne, Clermont-Ferrand, France.
P3-14-20 Neoadjuvant chemotherapy in young age breast cancer: Survival benefit over adjuvant chemotherapy in clinically T2 node positive patients
Kim MK, Moon H-G, Kim J, Lee JW, Kim J, Lee ES, Yoo T-K, Noh D-Y, Han W. Seoul National University Hospital, Seoul, Korea.
P3-14-21 Neoadjuvant chemotherapy in gynecologic oncology practices in Germany: A real life documentation
Schilling J, Hindenburg H-J, Klare P, Wetzel A, Klare K, Orthner P. BNGO e.V., Schöneiche b. Berlin, Brandenburg, Germany; Gynäkologisch Onkologische Schwerpunktpraxis, Berlin, Germany; Praxisklinik Krebsheilkunde, Berlin, Germany; Pomme-med, Munich, Bavaria, Germany.
P3-14-22 Positive prognostic value of a high-to-low change in neutrophil-to-lymphocyte ratio after neoadjuvant chemotherapy in patients with breast cancer
Ou-Yang Q-W, Jiang Y-Z, Shao Z-M, Yu K-D, Luo R-C, Cui W-Q. The Third Hospital of Nanchang, Nanchang, JiangXi, China; Fudan University Shanghai Cancer Center, Shanghai, China; Sounthern Medical University, Guangzhou, GuangDong, China.
   
  Treatment: Toxicities Management
P3-15-01 Withdrawn
P3-15-02 A prospective, open label, non-comparative trial to determine the incidence of chemotherapy-induced nausea and vomiting associated with the docetaxel-cyclophosphamide regimen in early breast cancer patients. Results from the GEICAM 2009-02 study
Carañana V, Ramos M, Damau E, García-Saenz JA, González X, Murillo L, Calvo L, Morales S, González-Farré A, Fernández-Morales LA, Carrasco E, Casas MI, Angulo MdM, Cámara MC, García AI, Llombart A, Jara C. Hospital Arnau de Vilanova, Valencia, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Corporació Sanitaria Par Tauli, Sabadell, Barcelona, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Clinic i Provincial, Barcelona, Spain; Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Arnau de Vilanova, Lleida, Spain; GEICAM (Spanish Breast Cancer Research Group), Madrid, Spain; Fundación Hospital Alrcorcón, Alcorcón, Madrid.
P3-15-03 Safety analysis of BOLERO-3: A phase 3 trial of daily everolimus (EVE) vs placebo (PBO), both with weekly trastuzumab (TRAS) and vinorelbine in trastuzumab-resistant, advanced breast cancer
Jerusalem G, Masuda N, André F, Fein L, Fasolo A, O'Regan R, Wilks S, Isaacs C, Zhang Y, Taran T, Toi M. CHU Sart Tilman Liege, Liege, Belgium; NHO Osaka National Hospital, Osaka, Japan; Institut Gustave Roussy, Villejuif, France; Instituto De Oncologia De Rosario, Rosario, Santa Fe, Argentina; San Raffaele Cancer Center, Milan, Italy; Winship Cancer Institute of Emory University, Atlanta, GA; Cancer Care Center of South Texas, TX; Georgetown University, Washington, DC; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Kyoto University Hospital, Kyoto, Japan.
P3-15-04 A French prospective pilot study to identify dihydropyrimidine dehydrogenase (DPD) deficiency in breast cancer patients receiving capecitabine
Milano G, Ferrero J-M, Thomas F, Bobin-Dubigeon C, Merlin J-L, Pinguet F, Ferrand C, Boyer J-C, Romieu G, Bachelot T, Pivot X, Dieras V, Largillier R, Mousseau M, Goncalves A, Roche H, Bonneterre J, De Clercq B, Etienne-Grimaldi M-C. Centre Antoine-Lacassagne, Nice, France; Centre Clauduis-Regaud, Toulouse, France; Institut de Cancérologie du de l'Ouest, Nantes-Angers, France; Centre Alexis-Vautrin, Nancy, France; Centre Paul Lamarque, Montpellier, France; CHU de Besançon, Besançon, France; CHU de Nîmes, Nîmes, France; Centre Léon Berard, Lyon, France; Institut Curie, Paris, France; Centre Azuréen de Cancérologie, Mougins, France; CHU de Grenoble, Grenoble, France; Institut Paoli Calmettes, Marseille, France; Centre Oscar Lambret, Lille, France.
P3-15-05 Risk and consequences of neutropenic complications with adjuvant use of trastuzumab and chemotherapy in women with metastatic breast cancer
Weycker D, Li X, Kartashov A, Barron R, Edelsberg J, Xu H, Girardi V, Lyman G. Policy Analysis Inc. (PAI), Brookline, MA; Amgen Inc., Thousand Oaks, CA; Duke University, Durham, NC.
P3-15-06 Results of the MARS study on the management of antiangiogenics' renovascular safety in breast cancer
Gligorov J, Janus N, Daniel C, Beuzeboc P, Ray-Coquard I, Rey J-B, Jouannaud C, Spano J-P, Thery J-C, Morere J-F, Goldwasser F, Mir O, Scotté F, Oudard S, Azizi M, Dorent R, Deray G, Launay-Vacher V. Hôpital Tenon, Paris, France; Service ICAR, Hôpital de la Pitié-Salpêtrière, Paris, France; Institut Curie, Paris, France; Centre Léon Bérard, Lyon, France; Institut Jean Godinot, Reims, France; Hôpital de la Pitié-Salpêtrière, Paris, France; Hôpital Avicenne, Bobigny, France; Hôpital Cochin, Paris, France; Hôpital Européen Georges Pompidon, Paris, France; Arterial Hypertensive, Hôpital Européen Georges Pompidon, Paris, France; Cardiology, Hôpital Européen Georges Pompidon, Paris, France; Nephrology, Hôpital de la Pitié-Salpêtrière, Paris, France.
P3-15-07 Cutaneous toxicity and recovery: Is there a difference between breast cancer patients treated with daily radiotherapy in the morning versus the afternoon?
Lee A, Yang X, Mister D, Liu T, Torres MA. Emory University, Atlanta, GA.
P3-15-08 A multicenter observational study to investigate the relationship between physician-assessed febrile neutropenia (FN) risk and prediction model FN or SN (severe neutropenia) risk in patients with breast cancer
Lyman GH, Dale DC, Legg JC, Abella E, Morrow PK, Whittaker S, Crawford JA. Duke University School of Medicine and The Duke Cancer Institute, Durham, NC; University of Washington, Seattle, WA; Amgen Inc., Thousand Oaks, CA.
P3-15-09 Impact of granulocyte colony-stimulating factors on febrile neutropenia risk during early-stage breast cancer treatment
Ben Abdallah SS, Letarte N, Messier C, Charpentier D, Yelle L, Younan R, Bestawros A. Centre Hospitalier de l'Université de Montréal Hôpital Notre-Dame, Montréal, QC, Canada.
P3-15-10 Human neuronal model to study chemotherapeutic-induced peripheral neuropathy
Dolan ME, Wing C, Komatsu M, Delaney SM, Wheeler HE. University of Chicago, Chicago, IL.
P3-15-11 Chemotherapy-related fatigue in low cardiac risk breast cancer patients: A sign of cardiotoxicity?
Marfatia R, Inyangetor D, Feinn RS, Adekolu O, Fellows D, Tannenbaum S, Avelar E. University of Connecticut Health Center, Farmington, CT; Frank H Netter, MD, School of Medicine, Medical Sciences, North Haven, CT.
P3-15-12 Echocardiography screening before anthracycline-containing chemotherapy has a relevant impact on treatment decisions
Mayr D, Hochreiner G, Fuchs D, Fridrik MA. Internal Medicine 3, General Hospital Linz, Linz, Austria; General Hospital Linz, Linz, Austria.
   
 
Home | About SABCS | Press Releases | Media | Event Photos | Past Symposia | Satellite Symposia | Patient Advocates | FAQs | Contact Us
Registration | Hotel | Support & Exhibits | 2014 Overview | Program | Travel & Transportation

Rich Markow, Director, Symposia
Cancer Therapy & Research Center at UT Health Science Center San Antonio

7979 Wurzbach Road, MC 8224 San Antonio, TX 78229 USA
Phone: 210-450-1550    Fax: 210-450-1560    Email: sabcs@uthscsa.edu
       line
Copyright © 2014 SABCS. All rights reserved. - Privacy Policy